



Investment Science

Scientifically sound consulting and investing



VISION

- Welcome to an unparalleled investment opportunity – a chance to shape a better world while securing financial returns. Investment Science is breaking down the barriers between cutting-edge innovations and strong investment opportunities.

Picture this:

Your capital acts as a conduit, flowing into diverse workstreams.

Our journey commences with standby letters of credit featuring dynamic buy-sell programs. Through our strategic alliance with TheraPharma Consulting, we wield direct access to finance ministers across the Department of Commerce.

What sets us apart?

Government guarantees underpin our projects, spanning from revolutionary nuclear power initiatives to groundbreaking medical isotope ventures with cancer-curing potential.

Your desire for returns aligns seamlessly with our commitment to a thrilling humanitarian agenda. This isn't just an investment; it's a transformative force. Join us on this journey where financial prosperity converges with the fulfillment of impactful global initiatives. Seize the opportunity to be part of something greater – where your investment doesn't just grow but contributes to a world of positive change.





INVESTMENT SCIENCE

Investment Science was founded in 2015 with a mission to provide innovative solutions and expertise in the banking and technology sectors. We serve a diverse clientele, including financial institutions, NGOs, technology service firms, and individuals seeking financial planning or insurance services. Our focus is on delivering objective advice and efficient solutions tailored to the unique needs of each sector we serve.

Our primary offering is the SageFusion Artificial Intelligence Asset Management Platform, designed specifically for accredited investors. This platform provides transparent and objective advice, empowering clients to make informed decisions about their financial futures. Whether clients seek to diversify capital or explore alternative investment measures like launching ETFs or issuing bonds at 85% of net income, our platform serves as a trusted advisor, offering a second opinion on investments.



SageFusion
Artificial Intelligence Asset
Management Platform,
designed specifically for
accredited investors

CHALLENGE

The global energy landscape desperately needs sustainable alternatives to traditional fossil fuels. This shift is underscored by international agreements prioritizing alternative energy sources, as highlighted by the International Energy Agency's report on the accelerating growth of renewable electricity worldwide. However, this transition encounters obstacles such as limited accessibility and insufficient funding. In response, Therapharma emerges as a leader in the alternative energy sector, presenting a pioneering thorium nuclear reactor concept sponsored by the Department of Energy.

With a guaranteed return on investment, TheraPharma's thorium nuclear reactor offers a novel and consistent source of clean energy, devoid of nuclear waste and scalable to meet rising energy needs. Additionally, it yields valuable medical isotopes for medical applications, addressing critical gaps in cancer treatment. TheraPharma's unique business model addresses the energy industry's void by offering a secure and lucrative investment avenue in sustainable energy solutions. Through licensing agreements priced at \$57 million and 12% of the thorium's value, investors have a compelling opportunity to profit from the transition to clean energy.





SOLUTION

Investment Science offers SageFusion, a treasury management platform designed to address prevalent challenges in the investment landscape, such as inadequate risk management and exorbitant fees. A striking statistic reveals that 81% of global wealth funds underperformed the S&P 500, highlighting the imperative for effective risk mitigation strategies. Therapharma mitigates this risk by pledging mining assets to be monetized, issuing bonds on our nuclear patents, and leveraging SageFusion for treasury management.

COMPETITION

Investment Science business distinguishes itself from the competition through its innovative approach, transparent business model, and extensive network. With a commitment to delivering value and driving growth in emerging sectors, we are well-positioned to capitalize on market opportunities and establish ourselves as leaders in both global wealth management and environmental economics.

With access to government contracts, financial executives, and exclusive insurance products through Lloyd's of London, we provide unparalleled resources for our clients. Our extensive portfolio, including 150 physical mining assets, nuclear patents, government contacts, and connections with world leaders, sets us apart from competitors and strengthens our position in the market.

We serve a variety of clients



Deutsche Bank

Dimensional

EY

FitchSolutions

GOLDEN CAP VENTURES

KKR

And a range of markets

PLAN

SageFusion boasts a proven track record, delivering a remarkable 55% return from 2021 to 2023. Therapharma is poised for international expansion by 2026, with plans to construct a prototype by 2025, supported by a fuel validation report scheduled for 2024. Additionally, our extensive patent portfolio and government assets serve as collateral, enhancing investor security. By investing in Therapharma, investors





not only stand to gain substantial returns but also contribute to the global transition to clean energy and cancer treatment.

Investment Science provides investors with a secure and lucrative opportunity to capitalize on the growing demand for cutting-edge innovations, such as clean energy solutions, while addressing key challenges facing traditional investment vehicles, leveraging alternative financing solutions such as mining assets.

TEAM

- A diverse and experienced leadership team is poised to drive the company forward and capitalize on market opportunities, leveraging a go-to-market strategy that encompasses 150 mining assets through alternative financing solutions, nuclear patents bond raises, and Lloyd's of London insurance products.

Michael Kelly
 Founder & CEO

Dr. Andy Weinbach
 Strategic Advisor

Lonn Litchfield
 Partner and
 General Counsel

Cecil Davis
 Board
 Member

Andrew Barlow
 Chief Marketing
 Consultant

Ryan Landry
 Partner Arbitrage
 Consultant

MILESTONES

This timeline showcases the progression of past achievements and provides a glimpse into future goals and targets.



2021

Achieved 2% Alpha with SageFusion. System design and development phase initiated.

2023

Government assets backed SageFusion software, including 150 mines, government contracts, and nuclear patents bond raise. Engaged in SBLC buy-sells.

2024

Develop and grow partnerships. Expand political support and acquire additional mining assets.

2025

Continue to enhance SageFusion with system upgrades and AI refinement. Scale up AUM.





FINANCIALS

Investment Science is seeking investment of \$20 million, which will be leveraged for a \$200 million loan which will be disbursed over 24 months. The financial projections below cover the past two years to substantiate revenue for the business; Year 0 is 2024.

Operating Statements	Year -2	Year -1	Year 0	Year 1	Year 2
Revenue					
Investment Science	187,000	150,000	1,250,000	2,000,000	8,000,000
TheraPharma Consulting	0	0	238,500,000	671,500,000	1,401,500,000
SageFusion	0	0	35,775,000	39,352,500	43,287,750
Cost of Goods Sold (0%)	0	0	0	0	0
Net Revenue	187,000	150,000	275,525,000	712,852,500	1,452,787,750
Operating Expenses					
Investment Science	187,000	150,000	800,000	1,600,000	2,000,000
TheraPharma Consulting	0	0	19,000,000	67,000,000	43,000,000
SageFusion	0	0	800,000	900,000	1,500,000
Total Operating Expenses	187,000	150,000	20,600,000	69,500,000	46,500,000
Pre-Tax Income	0	0	254,925,000	643,352,500	1,406,287,750

Source and Use of Funds

Source of Funds

Investor	0	0	20,000,000	0	0
Grants	0	0	0	0	300,000,000
Sovereign Fund Loan Distributions	0	0	66,666,667	100,000,000	33,333,333

Use of Funds (1x set up)

Sovereign Fund downpayment	0	0	-20,000,000		
Investment Science	0	0	-6,666,667	-10,000,000	-3,333,333
TheraPharma Consulting	-3,000,000	-3,000,000	-56,666,667	-85,000,000	-28,333,333
SageFusion	0	0	-3,333,333	-5,000,000	-1,666,667

Investor & Loan Repayment

Investor Repayment	0	0	-2,550,000	-5,000,000	-5,000,000
--------------------	---	---	------------	------------	------------

(up to max of \$20m)

Investor Repayment

Investor Repayment	0	0	0	0	0
--------------------	---	---	---	---	---

(20% of pre-tax income after loan paid)

Sovereign Fund Interest Payments	0	0	-25,500,000	-123,250,000	-199,750,000
---	----------	----------	--------------------	---------------------	---------------------

Operating Income/ (Losses)	0	0	254,925,000	643,352,500	1,406,287,750
----------------------------	---	---	-------------	-------------	---------------

Total Operating Expenses	-3,000,000	-3,000,000	140,208,333	415,102,500	1,168,204,417
---------------------------------	-------------------	-------------------	--------------------	--------------------	----------------------

Net Change	-3,000,000	-3,000,000	226,875,000	515,102,500	1,501,537,750
-------------------	-------------------	-------------------	--------------------	--------------------	----------------------

Cash at Beginning of Period

Cash at Beginning of Period	0	-3,000,000	-6,000,000	220,875,000	735,977,500
-----------------------------	---	------------	------------	-------------	-------------

Net Change	-3,000,000	-3,000,000	226,875,000	515,102,500	1,501,537,750
------------	------------	------------	-------------	-------------	---------------

Cash at End of Period	-3,000,000	-6,000,000	220,875,000	735,977,500	2,237,515,250
------------------------------	-------------------	-------------------	--------------------	--------------------	----------------------





CONCLUSIONS

This team at Investment Science has spent the past few years developing the SageFusion platform and validating the capabilities in collaboration with TheraPharma. They are now seeking \$20 million in investment to take the business forward.

Join us on this journey where financial prosperity converges with the fulfillment of impactful global initiatives. Seize the opportunity to be part of something greater – where your investment doesn't just grow but contributes to a world of positive change.



Investment Science

A journey where
financial prosperity
converges with the
fulfillment of
impactful global
initiatives

REAGAN RODRIGUEZ
Reagan@5thaavc.com | 800.201.3143



5th Avenue Capital
Private Funding from \$10M to \$2B